<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756154</url>
  </required_header>
  <id_info>
    <org_study_id>EM-05-014624</org_study_id>
    <nct_id>NCT04756154</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Patient Preoperative Preps In-vivo</brief_title>
  <official_title>Assessment of the Antimicrobial Efficacy of 3M™ SoluPrep™ Preoperative Skin Preparation Against Resident Human Skin Flora on the Inguinal Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3M</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the antimicrobial efficacy of an investigational&#xD;
      CHG/IPA prep on skin flora of the inguinal regions of human subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Log change in skin flora on the inguinal region at 10 minutes</measure>
    <time_frame>10 minutes</time_frame>
    <description>Immediate efficacy endpoint which is defined as the average treatment effect (ATE) log10 CFU/cm2 of skin flora on the inguinal region at 10 minutes following application of the study products relative to the treatment day baseline skin flora</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Log change in skin flora on the inguinal region at 6 hours</measure>
    <time_frame>6 hours</time_frame>
    <description>Persistent efficacy endpoint which is a binary endpoint with success/failure, where &quot;success&quot; is defined as log10 CFU/cm2 of skin flora on the inguinal region at 6 hours following application of the study products being lower than the treatment day baseline skin flora</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Surgical Skin Preparation</condition>
  <arm_group>
    <arm_group_label>SP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SPFF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHG/IPA Surgical skin preparation</intervention_name>
    <description>Apply topically</description>
    <arm_group_label>SP</arm_group_label>
    <arm_group_label>SPFF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Apply topically</description>
    <arm_group_label>S</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects of any race&#xD;
&#xD;
          -  Subjects in good health&#xD;
&#xD;
          -  Minimum skin flora baseline requirements on inguinal region&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin&#xD;
             disorders (including acne) on the applicable test area&#xD;
&#xD;
          -  Topical antimicrobial exposure within 14 days prior to screening and treatment days&#xD;
&#xD;
          -  Use of systemic or topical antibiotics, steroid medications, or any other products&#xD;
             known to affect the normal microbial flora of the skin within 14 days prior to&#xD;
             screening and treatment days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad H Bashir, MD, CCRP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Microbac</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad H Bashir, MD, CCRP</last_name>
    <phone>703-925-0100</phone>
    <email>muhammad.bashir@microbac.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Microbac Laboratories, Inc</name>
      <address>
        <city>Sterling</city>
        <state>Virginia</state>
        <zip>20164</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad H Bashir, MD, CCRP</last_name>
      <phone>703-925-0100</phone>
      <email>muhammad.bashir@microbac.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

